Treatment of Ischemic Stroke by Atorvastatin-Loaded PEGylated Liposome

Overview

Journal Transl Stroke Res

Publisher Springer

Date 2023 Jan 13

PMID 36639607

Authors

Reju George Thomas

Ja-Hae Kim

Ji-Hye Kim

Jungwon Yoon

Kang-Ho Choi

Yong-Yeon Jeong

Affiliations

Soon will be listed here.

Abstract

There is insufficient evidence on the effect of nanoparticles, particularly liposomes loaded with a statin, on acute ischemic stroke. We investigated the impact of atorvastatin-loaded PEG (polyethylene glycol) conjugated liposomes (LipoStatin) on the outcomes in rats with cerebral ischemia-reperfusion. PEGylated liposome loaded with atorvastatin was developed as a nanoparticle to specifically accumulate in an ischemic region and release the drug to ameliorate the harmful effects of the stroke. LipoStatin was administered to rats with transient middle cerebral artery occlusion through the tail vein immediately after reperfusion (LipoStatin group). LipoStatin efficiently accumulated at the cerebral ischemic injury site of the rat. The LipoStatin group showed a significantly reduced infarct volume (p < 0.01) in brain micro-MR imaging and improved neurological function recovery compared to the control group (p < 0.05). In addition, markedly improved brain metabolism using fluorine-18 fluorodeoxyglucose micro-PET/CT imaging was demonstrated in the LipoStatin group compared with the control group (p < 0.01). Mechanistically, as a result of evaluation through IL-1 beta, TNF-alpha, ICAM-1, and Iba-1 mRNA expression levels at 5 days after cerebral ischemia, LipoStatin showed significant anti-inflammatory effects. Protein expression of occludin, JAM-A, Caveolin-1, and eNOS by western blot at 3 days and fluorescent images at 7 days showed considerable recovery of blood-brain barrier breakdown and endothelial dysfunction. PEGylated LipoStatin can be more effectively delivered to the ischemic brain and may have significant neuroprotective effects. Thus, PEGylated LipoStatin can be further developed as a promising targeted therapy for ischemic stroke and other major vascular diseases.

Citing Articles

Utilization of nanotechnology to surmount the blood-brain barrier in disorders of the central nervous system.

Luo Q, Yang J, Yang M, Wang Y, Liu Y, Liu J Mater Today Bio. 2025; 31:101457.

PMID: 39896289 PMC: 11786670. DOI: 10.1016/j.mtbio.2025.101457.

Preparation of atorvastatin calcium-loaded liposomes using thin-film hydration and coaxial micromixing methods: A comparative study.

Dangkoub F, Bemani Naeini M, Akar S, Badiee A, Jaafari M, Sankian M Int J Pharm X. 2024; 8:100309.

PMID: 39697814 PMC: 11653151. DOI: 10.1016/j.ijpx.2024.100309.

Reactive Oxygen Species-Responsive Chitosan-Bilirubin Nanoparticles Loaded with Statin for Treatment of Cerebral Ischemia.

Raveena Nagareddy , Kim J, Kim J, Thomas R, Choi K, Jeong Y Biomater Res. 2024; 28:0097.

PMID: 39450150 PMC: 11499631. DOI: 10.34133/bmr.0097.

Targeted pathophysiological treatment of ischemic stroke using nanoparticle-based drug delivery system.

Liu W, Liu L, Li H, Xie Y, Bai J, Guan J J Nanobiotechnology. 2024; 22(1):499.

PMID: 39164747 PMC: 11337765. DOI: 10.1186/s12951-024-02772-2.

Innovations in Breaking Barriers: Liposomes as Near-Perfect Drug Carriers in Ischemic Stroke Therapy.

Zhang Q, Huang S, Liu X, Wang W, Zhu Z, Chen L Int J Nanomedicine. 2024; 19:3715-3735.

PMID: 38681090 PMC: 11046314. DOI: 10.2147/IJN.S462194.

References

Powers W, Rabinstein A, Ackerson T, Adeoye O, Bambakidis N, Becker K . 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018; 49(3):e46-e110. DOI: 10.1161/STR.0000000000000158. View

Goyal M, Menon B, van Zwam W, Dippel D, Mitchell P, Demchuk A . Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016; 387(10029):1723-31. DOI: 10.1016/S0140-6736(16)00163-X. View

Chen J, Jin J, Li K, Shi L, Wen X, Fang F . Progresses and Prospects of Neuroprotective Agents-Loaded Nanoparticles and Biomimetic Material in Ischemic Stroke. Front Cell Neurosci. 2022; 16:868323. PMC: 9035592. DOI: 10.3389/fncel.2022.868323. View

Dong X, Gao J, Su Y, Wang Z . Nanomedicine for Ischemic Stroke. Int J Mol Sci. 2020; 21(20). PMC: 7590220. DOI: 10.3390/ijms21207600. View

Shi L, Zhang J, Zhao M, Tang S, Cheng X, Zhang W . Effects of polyethylene glycol on the surface of nanoparticles for targeted drug delivery. Nanoscale. 2021; 13(24):10748-10764. DOI: 10.1039/d1nr02065j. View

Askarizadeh A, Butler A, Badiee A, Sahebkar A . Liposomal nanocarriers for statins: A pharmacokinetic and pharmacodynamics appraisal. J Cell Physiol. 2018; 234(2):1219-1229. DOI: 10.1002/jcp.27121. View

Amarenco P, Bogousslavsky J, Callahan 3rd A, Goldstein L, Hennerici M, Rudolph A . High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006; 355(6):549-59. DOI: 10.1056/NEJMoa061894. View

Hong H, Zeng J, Kreulen D, Kaufman D, Chen A . Atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke. Am J Physiol Heart Circ Physiol. 2006; 291(5):H2210-5. DOI: 10.1152/ajpheart.01270.2005. View

Vaughan C, Delanty N . Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke. 1999; 30(9):1969-73. DOI: 10.1161/01.str.30.9.1969. View

10.

Naci H, Brugts J, Fleurence R, Tsoi B, Toor H, Ades A . Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials. Eur J Prev Cardiol. 2013; 20(4):641-57. DOI: 10.1177/2047487313480435. View

11.

Sicard K, Fisher M . Animal models of focal brain ischemia. Exp Transl Stroke Med. 2010; 1:7. PMC: 2820445. DOI: 10.1186/2040-7378-1-7. View

12.

Jeong Y, Cheon S, Kang D, Kim J . F-18 FP-CIT PET in Multiple System Atrophy of the Cerebellar Type: Additional Role in Treatment. Contrast Media Mol Imaging. 2018; 2017:8598705. PMC: 5733227. DOI: 10.1155/2017/8598705. View

13.

Rodriguez-Yanez M, Castillo J . Role of inflammatory markers in brain ischemia. Curr Opin Neurol. 2008; 21(3):353-7. DOI: 10.1097/WCO.0b013e3282ffafbf. View

14.

Rezaie-Majd A, Prager G, Bucek R, Schernthaner G, Maca T, Kress H . Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2003; 23(3):397-403. DOI: 10.1161/01.ATV.0000059384.34874.F0. View

15.

Ito D, Tanaka K, Suzuki S, Dembo T, Fukuuchi Y . Enhanced expression of Iba1, ionized calcium-binding adapter molecule 1, after transient focal cerebral ischemia in rat brain. Stroke. 2001; 32(5):1208-15. DOI: 10.1161/01.str.32.5.1208. View

16.

Wei G, Dawson V, Zweier J . Role of neuronal and endothelial nitric oxide synthase in nitric oxide generation in the brain following cerebral ischemia. Biochim Biophys Acta. 1999; 1455(1):23-34. DOI: 10.1016/s0925-4439(99)00051-4. View

17.

Huang Q, Zhong W, Hu Z, Tang X . A review of the role of cav-1 in neuropathology and neural recovery after ischemic stroke. J Neuroinflammation. 2018; 15(1):348. PMC: 6302517. DOI: 10.1186/s12974-018-1387-y. View

18.

Zarruk J, Garcia-Yebenes I, Romera V, Ballesteros I, Moraga A, Cuartero M . Neurological tests for functional outcome assessment in rodent models of ischaemic stroke. Rev Neurol. 2011; 53(10):607-18. View

19.

Selim M, Molina C . High-dose statin for every stroke: the good, the bad, and the unknown. Stroke. 2012; 43(7):1996-7. DOI: 10.1161/STROKEAHA.111.648832. View

20.

Kleindorfer D, Towfighi A, Chaturvedi S, Cockroft K, Gutierrez J, Lombardi-Hill D . 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021; 52(7):e364-e467. DOI: 10.1161/STR.0000000000000375. View